{"disease":{"id":"phase-i","name":"phase i"},"drugs":{"marketed":[{"drug_id":"bosutinib","indication_name":"Blastic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bosulif","generic_name":"bosutinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"Kinase Inhibitor","quality_score":75,"revenue":"611","mechanism":"Bosulif works by blocking the activity of a specific enzyme called tyrosine-protein kinase ABL1, which is involved in the growth and survival of cancer cells."},{"drug_id":"bosulif","indication_name":"Blastic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bosulif","generic_name":"Bosutinib Monohydrate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"Kinase Inhibitor","quality_score":75,"revenue":"611","mechanism":"Bosulif blocks the abnormal tyrosine kinase activity in cancer cells, inhibiting their growth and proliferation."},{"drug_id":"dasatinib","indication_name":"Blastic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sprycel","generic_name":"dasatinib","company_name":"Handa Therap","drug_phase":"marketed","molecular_target":"Ephrin type-B receptor 6","drug_class":"dasatinib","quality_score":74,"revenue":"493","mechanism":"Sprycel works by blocking the activity of a specific protein called Ephrin type-B receptor 6, which is involved in the growth and survival of cancer cells."},{"drug_id":"dasatinib","indication_name":"Chronic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sprycel","generic_name":"dasatinib","company_name":"Handa Therap","drug_phase":"marketed","molecular_target":"Ephrin type-B receptor 6","drug_class":"dasatinib","quality_score":74,"revenue":"493","mechanism":"Sprycel works by blocking the activity of a specific protein called Ephrin type-B receptor 6, which is involved in the growth and survival of cancer cells."},{"drug_id":"nilotinib","indication_name":"Chronic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tasigna","generic_name":"NILOTINIB","company_name":"Cipla","drug_phase":"marketed","molecular_target":"Bcr/Abl fusion protein","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":"400","mechanism":"Tasigna works by blocking the abnormal Bcr/Abl protein that drives the growth of cancer cells in CML."},{"drug_id":"gleevec","indication_name":"Blastic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"gleevec","indication_name":"Chronic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"imatinib","indication_name":"Blastic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"imatinib","indication_name":"Chronic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"tasigna","indication_name":"Chronic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tasigna","company_name":"XSpray Microparticles","drug_phase":"marketed","molecular_target":"Ferrochelatase, mitochondrial, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase MRCK beta","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"odm-108-part-iii","indication_name":"Indication under Phase 1 evaluation (not specified)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ODM-108 Part III","company_name":"Orion Corporation, Orion Pharma","drug_phase":"discontinued","molecular_target":"Not publicly disclosed","drug_class":"Unknown — investigational small molecule","quality_score":null,"revenue":null,"mechanism":"ODM-108 mechanism of action is not publicly disclosed; Phase 1 evaluation focused on safety and pharmacokinetics in healthy volunteers."},{"drug_id":"odm-108-part-i","indication_name":"Indication under Phase 1 evaluation (not specified)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ODM-108 Part I","company_name":"Orion Corporation, Orion Pharma","drug_phase":"discontinued","molecular_target":"Not disclosed","drug_class":"Small molecule (investigational)","quality_score":null,"revenue":null,"mechanism":"ODM-108 Part I mechanism of action is not publicly disclosed; Phase 1 development was terminated."},{"drug_id":"pf-07899895","indication_name":"Undisclosed indication (Phase 1 terminated)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07899895","generic_name":"pf-07899895","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Not disclosed","drug_class":"Unknown","quality_score":null,"revenue":null,"mechanism":"Mechanism of action not disclosed; Phase 1 study terminated before pharmacological characterization."}],"offLabel":[],"totalMarketed":10,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT06785870","title":"EVAluation of Erythrocytosis PRospEctive Cohort STudy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Cyrus Hsia","has_results":false},{"nct_id":"NCT05249920","title":"Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1362,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT06406218","title":"The Impact of Phase I Cardiac Rehabilitation on the Prognosis of AMI Patients After PCI","phase":"NA","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"Han Yaling, MD","has_results":false},{"nct_id":"NCT03651635","title":"MR-proADM and CT-proET-1 During ICU Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":533,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT02115295","title":"Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":508,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03647215","title":"CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey","phase":"","overall_status":"COMPLETED","enrollment_count":427,"lead_sponsor_name":"Incyte Biosciences UK","has_results":false},{"nct_id":"NCT01897571","title":"Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Epizyme, Inc.","has_results":true},{"nct_id":"NCT07498634","title":"Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":323,"lead_sponsor_name":"Zhejiang Kanova Biopharmaceutical Co., LTD","has_results":false},{"nct_id":"NCT01582776","title":"Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":317,"lead_sponsor_name":"The Lymphoma Academic Research Organisation","has_results":false},{"nct_id":"NCT07426120","title":"Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Psoriasis Research Institute of Guangzhou","has_results":false},{"nct_id":"NCT02160054","title":"Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)","phase":"","overall_status":"COMPLETED","enrollment_count":289,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT06188611","title":"A Phase IV Study of Huazhi Rougan Granule","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":282,"lead_sponsor_name":"Shandong New Time Pharmaceutical Co., LTD","has_results":false},{"nct_id":"NCT01593254","title":"Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":262,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT06949644","title":"Pupillometry in Delayed Sleep Wake Phase Disorder","phase":"NA","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT05876949","title":"AVT03 With Xgeva in Healthy Male Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":208,"lead_sponsor_name":"Alvotech Swiss AG","has_results":true},{"nct_id":"NCT04677439","title":"Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Shenzhen Second People's Hospital","has_results":false},{"nct_id":"NCT06163430","title":"A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Terns, Inc.","has_results":false},{"nct_id":"NCT03459534","title":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":173,"lead_sponsor_name":"Il-Yang Pharm. Co., Ltd.","has_results":false},{"nct_id":"NCT06665412","title":"Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML","phase":"","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"Il-Yang Pharm. Co., Ltd.","has_results":false},{"nct_id":"NCT02689440","title":"Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03948022","title":"Luteal Support in Frozen-Thawed Embryo Transfer Cycles","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Centrum Clinic IVF Center","has_results":false},{"nct_id":"NCT04087408","title":"Role of Triptorelin 0.1 mg as a Luteal Phase Support in Assisted Reproductive Technique After Embryo Transfer : a Randomized Controlled Trial","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Moustafa Mohammed Abouelea","has_results":false},{"nct_id":"NCT00254423","title":"Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT05484193","title":"GnRH Agonist for Luteal Phase Support.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Shaare Zedek Medical Center","has_results":false},{"nct_id":"NCT03734770","title":"Patient's Preferences About Subcutaneous or Vaginal Progesterone Administration for Luteal Phase Support","phase":"NA","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"Universita di Verona","has_results":false},{"nct_id":"NCT03744468","title":"Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT06407258","title":"Promoting Sleep and Physical Activity Among Adolescent Psychiatric Patients","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Christin Lang","has_results":false},{"nct_id":"NCT00719888","title":"Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT00796068","title":"Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT01699217","title":"Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase","phase":"","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","has_results":false},{"nct_id":"NCT07175337","title":"Effect of Maryam Plant and Surah on Birth Pain, Anxiety and Satisfaction","phase":"NA","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Ataturk University","has_results":false},{"nct_id":"NCT01787487","title":"Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07537179","title":"Investigation of the Relationship Between MD, MLR and NLR With APRs in Sepsis in the ICU","phase":"","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Oguz Gundogdu","has_results":false},{"nct_id":"NCT03045120","title":"Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07432022","title":"A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":115,"lead_sponsor_name":"Shanghai EpimAb Biotherapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT03817398","title":"Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT00390793","title":"Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03932331","title":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":105,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02506933","title":"Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":102,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT02727803","title":"Personalized NK Cell Therapy in CBT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06302647","title":"Assessing Interest in Web/App Platforms for Early Phase Clinical Trial Recruitment","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Instituto de Investigación Hospital Universitario La Paz","has_results":false},{"nct_id":"NCT03589729","title":"Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03942094","title":"Nilotinib for First-line Newly Diagnosed CML-CP Patients","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Shenzhen Second People's Hospital","has_results":false},{"nct_id":"NCT03416400","title":"Comparison of Vitrification Effect Before or After In Vitro Maturation","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT04338867","title":"Nitroglycerin Plus Intracranial Radiotherapy for Brain Metastases in NSCLC Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Instituto Nacional de Cancerologia de Mexico","has_results":false},{"nct_id":"NCT02703571","title":"Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":95,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04693624","title":"Early Luteal Hormones and IVF Outcomes After hCG Triggering","phase":"","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Mỹ Đức Hospital","has_results":false},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT04423926","title":"Lenalidomide in Combination With CHOP in Patients With Untreated PTCL","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":91,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}